Funding
← Back to your selection

General Catalyst

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Healthtech · Jul 27, 2026

General Catalyst backs companies from formation and seed through growth, and also creates businesses with founders through its Creation strategy.

Creation includes starting companies in complex or emerging industries, helping experienced founders launch again and combining existing service businesses with applied AI. That makes GC relevant both to founders raising for an established startup and to entrepreneurs developing a new company with an investment partner.

For businesses that have reached product-market fit, its Customer Value Fund provides a separate way to finance customer acquisition. This sits alongside seed and growth equity, giving the firm a financing model directed specifically at the cost of expanding a customer base.

Sources
Rounds participated in
6
Confirmed lead rounds
1
All roles disclosed
New companies
4
First participation on record · 2 follow-on
Funding in participating rounds
$379.9M
6 disclosed · full round size, not this investor’s share

By stage

Series A2
Series B2
Series C+1
Undisclosed1

By primary sector

Healthtech6

By country

United States5
India1

Rounds

6 in this selection
Baba

Coordinates healthcare for Medicare members through dedicated advocates and licensed therapists supported by specialized AI.

$40MSeries A
Participant
Disha (formerly Curelink)

Disha, formerly Curelink, provides AI-assisted health coaching for diet, fitness and ongoing support with chronic conditions.

₹438.8MSeries A
Lead
Thatch

A health-benefits platform that lets employers set healthcare budgets while employees choose insurance and eligible care to fit their needs.

$108MNew funding
Participant
Evvy

Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health.

$40MSeries B
Participant
Forus

Connects healthcare providers, pharmacies, payers and biopharma through AI-assisted treatment-access workflows.

$150MSeries C
Participant
Faro AI

Structured data and AI agents for clinical development and pharmaceutical trial operations.

$37.3MSeries B
Participant